Teva Pharmaceutical Industries SG&A Expenses 2010-2024 | TEVA
Teva Pharmaceutical Industries annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Teva Pharmaceutical Industries sg&a expenses for the quarter ending March 31, 2024 were $0.886B, a 5.23% increase year-over-year.
- Teva Pharmaceutical Industries sg&a expenses for the twelve months ending March 31, 2024 were $3.542B, a 3.96% increase year-over-year.
- Teva Pharmaceutical Industries annual sg&a expenses for 2023 were $3.498B, a 1.54% increase from 2022.
- Teva Pharmaceutical Industries annual sg&a expenses for 2022 were $3.445B, a 2.35% decline from 2021.
- Teva Pharmaceutical Industries annual sg&a expenses for 2021 were $3.528B, a 3.9% decline from 2020.
Teva Pharmaceutical Industries Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$3,498 |
| 2022 |
$3,445 |
| 2021 |
$3,528 |
| 2020 |
$3,671 |
| 2019 |
$3,806 |
| 2018 |
$4,214 |
| 2017 |
$4,846 |
| 2016 |
$5,145 |
| 2015 |
$4,838 |
| 2014 |
$5,078 |
| 2013 |
$5,319 |
| 2012 |
$5,117 |
| 2011 |
$4,410 |
| 2010 |
$3,833 |
| 2009 |
$3,499 |
Teva Pharmaceutical Industries Quarterly SG&A Expenses
(Millions of US $) |
| 2024-03-31 |
$886 |
| 2023-12-31 |
$902 |
| 2023-09-30 |
$844 |
| 2023-06-30 |
$910 |
| 2023-03-31 |
$842 |
| 2022-12-31 |
$836 |
| 2022-09-30 |
$822 |
| 2022-06-30 |
$907 |
| 2022-03-31 |
$880 |
| 2021-12-31 |
$908 |
| 2021-09-30 |
$888 |
| 2021-06-30 |
$857 |
| 2021-03-31 |
$875 |
| 2020-12-31 |
$1,009 |
| 2020-09-30 |
$884 |
| 2020-06-30 |
$861 |
| 2020-03-31 |
$917 |
| 2019-12-31 |
$1,024 |
| 2019-09-30 |
$880 |
| 2019-06-30 |
$962 |
| 2019-03-31 |
$940 |
| 2018-12-31 |
$1,141 |
| 2018-09-30 |
$1,008 |
| 2018-06-30 |
$998 |
| 2018-03-31 |
$1,067 |
| 2017-12-31 |
$1,000 |
| 2017-09-30 |
$1,215 |
| 2017-06-30 |
$1,307 |
| 2017-03-31 |
$1,324 |
| 2016-12-31 |
$1,489 |
| 2016-09-30 |
$1,250 |
| 2016-06-30 |
$1,263 |
| 2016-03-31 |
$1,143 |
| 2015-12-31 |
$1,328 |
| 2015-09-30 |
$1,096 |
| 2015-06-30 |
$1,185 |
| 2015-03-31 |
$1,229 |
| 2014-12-31 |
$1,326 |
| 2014-09-30 |
$1,243 |
| 2014-06-30 |
$1,223 |
| 2014-03-31 |
$1,286 |
| 2013-12-31 |
$1,448 |
| 2013-09-30 |
$1,268 |
| 2013-06-30 |
$1,301 |
| 2013-03-31 |
$1,302 |
| 2012-12-31 |
$1,374 |
| 2012-09-30 |
$1,206 |
| 2012-06-30 |
$1,297 |
| 2012-03-31 |
$1,240 |
| 2011-12-31 |
$1,351 |
| 2011-09-30 |
$918 |
| 2011-06-30 |
$1,088 |
| 2011-03-31 |
$1,053 |
| 2010-12-31 |
$1,411 |
| 2010-09-30 |
$987 |
| 2010-06-30 |
$833 |
| 2010-03-31 |
$934 |
| 2009-12-31 |
$1,608 |
| 2009-09-30 |
$883 |
| 2009-06-30 |
$846 |
| 2009-03-31 |
$800 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$18.263B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
